This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jun;21(6):891-3.

doi: 10.1681/ASN.2010030262. Epub 2010 Apr 29.

Randomized intervention studies in human polycystic kidney and liver disease

Robert W Schrier

PMID: 20431043
DOI: 10.1681/ASN.2010030262

Editorial

Randomized intervention studies in human polycystic kidney and liver disease

Robert W Schrier. J Am Soc Nephrol. 2010 Jun.

. 2010 Jun;21(6):891-3.

doi: 10.1681/ASN.2010030262. Epub 2010 Apr 29.

Author

Robert W Schrier

PMID: 20431043
DOI: 10.1681/ASN.2010030262

No abstract available

PubMed Disclaimer

Comment on

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE. Hogan MC, et al. J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29. J Am Soc Nephrol. 2010. PMID: 20431041 Free PMC article. Clinical Trial.
Sirolimus therapy to halt the progression of ADPKD.
Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G. Perico N, et al. J Am Soc Nephrol. 2010 Jun;21(6):1031-40. doi: 10.1681/ASN.2009121302. Epub 2010 May 13. J Am Soc Nephrol. 2010. PMID: 20466742 Free PMC article. Clinical Trial.

Similar articles

[Autosomal dominant polycystic kidney disease].
Horie S. Horie S. Nihon Jinzo Gakkai Shi. 2011;53(1):6-9. Nihon Jinzo Gakkai Shi. 2011. PMID: 21370570 Review. Japanese. No abstract available.
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE. Hogan MC, et al. J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29. J Am Soc Nephrol. 2010. PMID: 20431041 Free PMC article. Clinical Trial.
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Serra AL, et al. N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26. N Engl J Med. 2010. PMID: 20581391 Clinical Trial.
Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Chrispijn M, et al. J Hepatol. 2013 Jul;59(1):153-9. doi: 10.1016/j.jhep.2013.03.004. Epub 2013 Mar 14. J Hepatol. 2013. PMID: 23499726 Clinical Trial.
Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
Wüthrich RP, Serra AL, Kistler AD. Wüthrich RP, et al. Kidney Blood Press Res. 2009;32(5):380-7. doi: 10.1159/000254338. Epub 2009 Nov 3. Kidney Blood Press Res. 2009. PMID: 19887826 Review.

See all similar articles

Cited by

TNF-α blockade is ineffective in animal models of established polycystic kidney disease.
Roix J, Saha S. Roix J, et al. BMC Nephrol. 2013 Oct 25;14:233. doi: 10.1186/1471-2369-14-233. BMC Nephrol. 2013. PMID: 24160989 Free PMC article.
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
Mekahli D, Decuypere JP, Sammels E, Welkenhuyzen K, Schoeber J, Audrezet MP, Corvelyn A, Dechênes G, Ong AC, Wilmer MJ, van den Heuvel L, Bultynck G, Parys JB, Missiaen L, Levtchenko E, De Smedt H. Mekahli D, et al. Pflugers Arch. 2014 Aug;466(8):1591-604. doi: 10.1007/s00424-013-1394-x. Epub 2013 Nov 6. Pflugers Arch. 2014. PMID: 24193408
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium. Meijer E, et al. Am J Kidney Dis. 2014 Mar;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. Epub 2013 Dec 15. Am J Kidney Dis. 2014. PMID: 24342522 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Wolters Kluwer
Medical
- MedlinePlus Health Information